Summary
The Valporate Safety Implementation Group (VSIG) is a clinically-led group set up to help facilitate the reduction of the use of sodium valporate in women and girls where there is a safer alternative.
Content
Sodium valporate carries a number of risks to the health of a developing fetus such as birth defects and problems with development and learning. The VSIG are working to reduce usage by 50% by 2023 and are supporting the implementation of the recommendations of the Independent Medicines and Medical Devices Safety (IMMDS) Review, published in July 2020.
Valproate Safety Implementation Group
https://www.england.nhs.uk/patient-safety/sodium-valproate/
0
reactions so far
0 Comments
Recommended Comments
There are no comments to display.
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now